Epitomics - an Abcam company. Visit our main site at abcam.com

Epitomics is now part of the Abcam family

Sep. 4th, 2012 Abcam acquires Epitomics Inc., the leader in Rabbit Monoclonal Antibody (RabMAb®) Technology

The leader of Rabbit Monoclonal Antibody, has joined Abcam, a global provider of protein research tools.

Now known as Epitomics – an Abcam Company, this extends Abcam’s product portfolio, including RabMAbs® research antibodies, EP Clone antibodies for Immunohistochemistry (In Vitro Diagnostics Range) and Custom Antibody Development Services, in line with the Abcam’s vision of becoming the world’s leading supplier of protein research tools.

Customers in many countries around the world will be able to purchase Epitomics products directly from Abcam and their authorized distributors starting on September 4, 2012. The leader of Rabbit Monoclonal Antibody, has joined Abcam, a global provider of protein research tools.

More information regarding the latest developments related to Epitomics and Abcam can be found here.

News

September 5, 2012
Abcam launches unique range of Epitomics’ RabMAbs®

September 4, 2012
Epitomics Rabbit Monoclonal Antibodies, Now Available Directly from Abcam in Europe Following Acquisition of Epitomics

July 25, 2012
New pathway map Epigenetic Histone Modifications - available now

June 12, 2012
Epitomics now offers Stable Cell Line Development Service

May 25, 2012
New pathway map ER Stress - available now

April 12, 2012
New pathway map Calcium Singaling - available now

March 12, 2012
New Spring Catalog available - request your copy today

February 29, 2012
Leica Microsystems and Epitomics Enter Agreement for Supply of Proprietary Rabbit Monoclonal Antibodies

December 21, 2011
Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions.

November 1, 2011
Epitomics, Inc. Receives Notice of Allowance from the United States Patent and Trademark Office for a novel Method for Identifying Differentially Expressed Proteins

September 2, 2011
New Fall Catalog available - request your copy today

July 26, 2011
Epitomics Releases New Antibodies Developed with the National Cancer Institute’s Center for Cancer Research

May 26, 2011
Epitomics Signs Agreement with Bayer for Antibody Technology

March 21, 2011
Dako and Epitomics enter into strategic alliance on developing and launching state-of-the-art IHC diagnostic monoclonal antibodies

January 20, 2011
Epitomics Signs Antibody Characterization Agreement with the National Cancer Institute

January 3, 2011
Epitomics now offers more than 9,000 primary antibodies

January 3, 2011
Epitomics Monthly $99 Antibody Special

December 15, 2010
Epitomics Signs Antibody Development Agreement with the National Cancer Institute

December 7, 2010
Epitomics Spin-Off Apexigen announces Antibody Collaboration with Centocor

September 20, 2010
Epitomics, Inc. announces worldwide availability of LRRK2 antibodies developed in partnership with the Michael J. Fox Foundation

August 12, 2010
Epitomics, Inc. announces Antibody Therapeutics Spin-Off Company Apexigen, Inc.

August 9, 2010
Epitomics Launches New Line of Rabbit Monoclonal Antibodies for the Anatomic Pathology Market

May 11, 2010
Amorfix and Epitomics enter into agreement to develop novel monoclonal antibodies against disease specific epitopes for the tratment of cancers

March 30, 2010
Epitomics launches conjugated Abs

March 25, 2010
RabMAbs as Source of Therapeutic Leads

February 11, 2010
Data Published in PLOS Demonstrates Therapeutic Potential of Rabbit Monoclonal Antibodies

February 10, 2010
Epitomics new Spring '10 Catalog now available

October 12, 2009
NEW BOOK - THERAPEUTIC MONOCLONAL ANTIBODIES: FROM BENCH TO CLINIC PROVIDES INDEPTH REVIEW OF TECHNOLOGIES AND LATEST ADVANCES IN ANTIBODY THERAPEUTICS

March 17, 2009
Epitomics Finalizes Settlement Agreement with Cell Signaling Technology

February 6, 2009
Bay Area Biotech Takes Role In Chinese Plan

January 21, 2009
Epitomics Signs Collaboration Agreement with Simcere to Develop Therapeutic Monoclonal Antibodies

December 16, 2008
EPITOMICS APPOINTS DR. ZHIQIANG AN AS CHIEF SCIENTIFIC OFFICER

December 9, 2008
EPITOMICS GRANTED ANTIBODY HUMANIZATION PATENT, SETTING STAGE FOR ENTRY INTO HUMAN THERAPEUTICS MARKET

October 24, 2008
EPITOMICS GRANTED UNIQUE ANTI-TNF ANTIBODY PATENT

October 23, 2008
EPITOMICS GRANTED PATENT ON NEXT GENERATION CELL LINE FOR PRODUCING RABBIT MONOCLONAL ANTIBODIES

May 27, 2008
EPITOMICS ANNOUNCES THE CREATION OF 1000th RABBIT MONOCLONAL ANTIBODY

May 6, 2008
Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies

September 6, 2007
Epitomics and Applied Genomics announce IHC diagnostic and clinical biomarker collaboration

August 21, 2007
Epitomics Patent for "An Immortalized Mammal Hybridoma Fusion Partner" allowed in Canada.

August 9, 2007
Epitomics Receives US Patent for "Cell Fusion Method"

August 9, 2007
Epitomics and Genentech extend Service and Licensing Agreement

June 29, 2007
Anti-Estrogen Receptor RabMAb Receives FDA Approval for Breast Cancer Diagnostic

January 18, 2007
Anti-Her2 RabMAb Receives FDA Approval for Breast Cancer Diagnostic

December 20, 2006
New Rabbit Monoclonal Antibody (SP1) is superior to Mouse Monoclonal Antibody (1D5) in predicting survival in breast cancer patients

October 18, 2005
Roche and Epitomics Enter Rabbit Monoclonal Antibody Technology Research Agreement

September 15, 2005
Epitomics Poster Wins Best Vendor Poster Award at the National Society for Histotechnology Convention.

August 25, 2005
Epitomics announces Phase I SBIR award on technology for quantitating protein phosphorylation from the National Institutes of Health